Veracyte Inc (VCYT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Veracyte Inc stock $30.29, price $24.16, upside +25.4%, quality 74 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $15.31 – $60.49 · fair‑value band $20.17 – $39.37 · the $24.16 price screens below the $30.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Veracyte in your weekly email
Every Wednesday you see whether Veracyte is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Show moreShow less
The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Stock analysis
Veracyte Inc (VCYT) currently trades at $24.16, while our model-based Fair Value estimate is $30.29, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $32.01 per share, and 13 of the 24 models we run sit above the $24.16 price.
Bear case: the Asset-Based group reads lowest at $4.88, and 11 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $20.17 (bear) to $39.37 (bull), the price of $24.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Veracyte Inc reported revenue of $517M in FY2025 versus $220M in FY2021, a compound +23.9%/yr. Reported net income was $66.4M in FY2025.
Key figures
Market cap $4.2B Mid · P/E ratio 37.5 · P/S ratio 7.51 · EPS (TTM) $1.40 · Net margin 20.4% · Return on equity 8.8% · Return on assets (EBIT) −2.3% (5-year average) · Operating margin 15.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 60% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 25%, VCYT screens cheaper than that median.
Fair Value models
Bear$20.17Fair Value $30.29Bull$39.37
Price $24.16 · Upside +25.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.20 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 10 officers or directors sold shares worth $12.5M and none bought.
SaleKarin EasthamDirector3× since Dec 5, 2025: 38,579 shares, avg. $47.92$1.8MOct 27, 202610b5-1 plan
SaleJens HolsteinDirector3× since Nov 20, 2025: 30,000 shares, avg. $45.19$1.4MOct 27, 202610b5-1 plan
SaleMuna BhanjiDirector2× since Sep 1, 2026: 3,728 shares, avg. $43.34$161,553Oct 19, 202610b5-1 plan
SaleJohn LeiteGlobal Chief Commercial Off5× since Nov 25, 2025: 27,336 shares, avg. $45.60$1.2MSep 21, 202610b5-1 plan
SalePhillip G. FebboChief Scientific & Med Officer2× since Mar 2, 2026: 26,535 shares, avg. $39.56$1.0MSep 4, 202610b5-1 plan
SaleRebecca ChambersChief Financial Officer4× since Dec 4, 2025: 38,832 shares, avg. $41.70$1.6MSep 4, 202610b5-1 plan
SaleAnnie McGuireEVP, General Counsel6× since Dec 4, 2025: 35,453 shares, avg. $41.28$1.5MSep 4, 202610b5-1 plan
SaleMarc StapleyChief Executive Officer, Director3× since Dec 4, 2025: 191,242 shares, avg. $46.63$8.9MJun 4, 202610b5-1 plan
SaleJonathan WygantVP, Chief Accounting Officer2× since Nov 10, 2025: 29,102 shares, avg. $44.86$1.3MMay 22, 2026
SaleRobert S EpsteinDirector10,000 shares at $44.01$440,100May 20, 202610b5-1 plan
Plus 1 more entries from the last 12 months.
Plus 24 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.5%
Start year 2020 (pandemic). Over 10 years: +26.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−30.1% (2020) → 14.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +3.5% a year for the price and +7.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Veracyte's strength is its Decipher Prostate test assessing progression risk where clinical factors alone leave uncertainty, yet low ROE signals thin evidence of a durable moat.
Main risk: Hurdles in updating treatment guidelines and payer policies would limit adoption and revenue growth from the enhanced Decipher test.
Veracyte is adding predictive power to its Decipher Prostate test through new Phase III analysis showing it can identify which intermediate-risk patients gain from short-term hormone therapy with radiation. This builds on its established role in assessing progression risk for a disease where clinical factors alone leave much uncertainty. Does stronger evidence for guiding therapy choices outweigh the typical hurdles of changing treatment guidelines and payer policies?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+25.4% · Top 25%
Profitability
Return on equity (12 months)8.8% · Above median
Return on assets4.7% · Above median
Net margin (12 months)20.4% · Top 25%
Operating margin (12 months)15.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)15.5% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)37.5× · Pricier than median
P/B3.22× · Pricier than median
P/S (12 months)7.51× · Priciest 25%
Price / free cash flow (fiscal year)33.3× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Veracyte Inc Fair Value". https://www.fairvalue-calculator.com/stock/VCYT
Frequently asked questions
Is Veracyte Inc (VCYT) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $30.29 versus a price of $24.16, about +25% upside (undervalued).
What is the fair value of VCYT?
Our model-based fair value for Veracyte Inc is $30.29 (as of Nov 6, 2026), built from audited fundamentals. The current price: $24.16.
What is the quality score of VCYT?
Veracyte Inc has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Veracyte Inc (VCYT)?
Our model-based price target is the fair value of $30.29 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $20.17, optimistic scenario $39.37. It is a calculation from audited fundamentals, not an analyst target.
What is the Veracyte Inc stock forecast for 2026?
Our models put fair value at $30.29, about +25% upside versus a price of $24.16 (undervalued). Cautious scenario $20.17, optimistic scenario $39.37. The calculation is refreshed regularly with new filings.
What is the revenue of Veracyte Inc (VCYT)?
Veracyte Inc reported trailing-twelve-month revenue of about $562M (latest available figure, as of Nov 6, 2026).
What growth is priced into Veracyte Inc (VCYT)?
For today's price to be fair in a discounted-cash-flow model, Veracyte Inc would have to grow free cash flow by +5.9 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +34.5 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of VCYT use?
Our models discount Veracyte Inc at 12.1 %: a base by market capitalisation (mid), damped by beta 1.96, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Veracyte Inc that is +5.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Veracyte Inc (VCYT) delivered so far?
Over the past 5 years revenue at Veracyte Inc grew +34.5 % a year. The price currently implies free-cash-flow growth of +5.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Veracyte Inc (VCYT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Veracyte Inc (+5.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Veracyte Inc (VCYT)?
The free-cash-flow yield on the price is 6.37 %: that much free cash flow Veracyte Inc produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Veracyte Inc (VCYT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Veracyte Inc it is $30.29 per share (as of Nov 6, 2026), against a price of $24.16. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Veracyte Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, VCYT trades below its calculated fair value: price $24.16, fair value $30.29, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VCYT?
No. The price is what the market pays today ($24.16); the fair value is what the company's own numbers justify ($30.29). For Veracyte Inc the two are $6.13 per share apart. That gap is exactly why we show both numbers side by side.
How much is Veracyte Inc worth?
The market values Veracyte Inc at about $4.2B (market capitalisation, as of Nov 6, 2026). Per share that is $24.16; our models calculate a fair value of $30.29 per share.
What do the bullish and bearish scenarios say about VCYT?
Our models span a range for Veracyte Inc: cautious scenario $20.17, base $30.29, optimistic $39.37 per share (as of Nov 6, 2026, price $24.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VCYT?
Veracyte Inc trades at a price-to-earnings ratio of 37.5 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $30.29 is built from several models across several years. Other multiples: P/B 3.2, P/S 7.5, EV/EBITDA 34.0.
How solid is the balance sheet of Veracyte Inc (VCYT)?
Balance-sheet figures for Veracyte Inc (as of Nov 6, 2026): return on equity 8.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is VCYT from its 52-week high?
Veracyte Inc trades at $24.16, about 60% below its 52-week high of $60.49 and 1% above the low of $24.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $30.29 is for.
Which stocks are comparable to Veracyte Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Veracyte Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $24.16, calculated fair value $30.29 (+25%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VCYT calculated?
We run Veracyte Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $30.29 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Veracyte Inc currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Veracyte Inc (VCYT)?
The closing price on Nov 6, 2026 was $24.16. Our model-based fair value is $30.29, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Veracyte Inc right now?
Solid quality (74/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($20.17 to $39.37) leaves room in how you read the outcome.
Key figures of Veracyte Inc
How large is the market capitalisation of Veracyte Inc (VCYT)?
The market capitalisation of Veracyte Inc is $4.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Veracyte Inc (VCYT)?
The price-to-sales ratio of Veracyte Inc is 7.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Veracyte Inc (VCYT)?
Earnings per share at Veracyte Inc are $1.40 (price ÷ EPS = P/E 37.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Veracyte Inc (VCYT)?
The net margin of Veracyte Inc is 20.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Veracyte Inc (VCYT)?
The return on equity (ROE) of Veracyte Inc is 8.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Veracyte Inc (VCYT)?
On an EBIT basis the return on assets of Veracyte Inc is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Veracyte Inc (VCYT)?
The operating margin of Veracyte Inc is 15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Veracyte Inc (VCYT)?
Revenue at Veracyte Inc is growing +15.5% versus a year earlier (3y avg +20.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Veracyte Inc (VCYT)?
Earnings per share at Veracyte Inc are growing +289% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Veracyte Inc (VCYT) hold?
Veracyte Inc holds more cash than debt, $323M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Veracyte Inc in the live analysis
One click puts Veracyte Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026